STOCK TITAN

Bausch Health To Reduce Debt By $150 Million Using Cash Generated From Operations

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

LAVAL, Quebec, Oct. 29, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that on Nov. 30, 2020 it will redeem (i) approximately $100 million aggregate principal amount of its outstanding 5.875% Senior Notes due 2023, CUSIP Nos. 91831A AB7, C96729 AB1 (the "5.875% Notes"), representing the entire outstanding amount of the 5.875% Notes and (ii) approximately $50 million aggregate principal amount of its outstanding 5.50% Senior Notes due 2023, CUSIP Nos. 91911K AE2, C94143 AE1 (the "5.50% Notes" and, together with the 5.875% Notes, the "Notes"), using cash generated from operations.

The Company will issue today irrevocable notices of redemption for each series of Notes and a copy will be issued to the record holders of such Notes. Nothing contained herein shall constitute a notice of redemption of the Notes. Payment of the redemption price and surrender of the Notes for redemption will be made through the facilities of the Depository Trust Company in accordance with the applicable procedures of the Depository Trust Company. The name and address of the U.S. paying agent are as follows: The Bank of New York Mellon Trust Company, N.A., c/o The Bank of New York Mellon; 111 Sanders Creek Parkway, East Syracuse, N.Y. 13057; Attn: Redemption Unit; Tel: 800-254-2826.

About Bausch Health 
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.

Caution Regarding Forward-Looking Information and "Safe Harbor" Statement 
This news release may contain forward-looking statements, including, but not limited to, the redemption of the Notes. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual and quarterly reports and detailed from time to time in the Company's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on the Company, including but not limited to its supply chain, third-party suppliers, project development timelines, employee base, liquidity, stock price, financial condition and costs (which may increase) and revenue and margins (both of which may decrease). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

Investor Contact:                                            

Media Contact:

Arthur Shannon                                                 

Lainie Keller

arthur.shannon@bauschhealth.com               

lainie.keller@bauschhealth.com

(514) 856-3855                                                

(908) 927-1198

(877) 281-6642 (toll free) 


Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.)

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bausch-health-to-reduce-debt-by-150-million-using-cash-generated-from-operations-301161829.html

SOURCE Bausch Health Companies Inc.

Bausch Health Companies Inc

NYSE:BHC

BHC Rankings

BHC Latest News

BHC Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing
CA
Laval

About BHC

bausch health companies inc. (nyse/tsx: bhc) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. we are delivering on our commitments as we build an innovative company dedicated to advancing global health. our approximately 22,000 employees are united around our mission of improving people’s lives with our health care products, and we manufacture and market health care products directly or indirectly in approximately 100 countries.five pillars, or guiding principles, represent the foundation on which we are realizing our mission as an organization: people, quality health care outcomes, customer focus, innovation and efficiency. more information can be found at www.bauschhealth.com.###